Showing results (71-80 of 111) with videos related to
Sort By:
Pageof 12
British Journal of Haematology|October 30, 2015
Coagulation activation in sickle cell trait: an exploratory studyChirag Amin, Soheir Adam, Micah J Mooberry, et al.BMC Blood Disorders|July 27, 2005
L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cellsYutaka Niihara, Neil M Matsui, Yamin M Shen, et al.Journal of Hematotherapy & Stem Cell Research|June 14, 2003
Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collectionAnand P Jillella, Celalettin Ustun, Eric Robach, et al.American Journal of Hematology|March 29, 2014
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseMarvin E Reid, Amal El Beshlawy, Adlette Inati, et al.Blood|January 15, 2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaKenneth I Ataga, Wally R Smith, Laura M De Castro, et al.American Journal of Hematology|October 9, 2018
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisAbdullah Kutlar, Julie Kanter, Darla K Liles, et al.American Journal of Hematology|August 14, 2012
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell diseaseAbdullah Kutlar, Kenneth Ataga, Marvin Reid, et al.Journal of Pediatric Hematology/Oncology|August 7, 2003
Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemiaLewis L Hsu, Scott T Miller, Elizabeth Wright, et al.American Journal of Hematology|July 6, 2013
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseAbdullah Kutlar, Marvin E Reid, Adlette Inati, et al.Annals of Hematology|April 20, 2024
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panelJulie Kanter, Kenneth I Ataga, Neha Bhasin, et al.Pageof 12